Pfizer (PFE) Gains FDA Breakthrough Therapy Designation for PF-06651600
September 5, 2018 8:51 AM
Pfizer Inc. (NYSE: PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
